|Bid||0.00 x 1300|
|Ask||0.00 x 2200|
|Day's Range||13.03 - 14.34|
|52 Week Range||11.22 - 29.65|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||80.17|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.33|
BJRI, CARA, BOOM, STNG, and UL have been added to the Zacks Rank #5 (Strong Sell) List on October 26, 2021.
Cara Therapeutics (NASDAQ:CARA) has had a rough month with its share price down 8.8%. It seems that the market might...
STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented results from the KARE Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. Results were presented by Brian Kim, MD, Associat